{"DataElement":{"publicId":"2936095","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria 061 Type","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_I_CTEC_061_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518231","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC977E8-B49D-6863-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2936083","version":"1","preferredName":"061 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for an AIDS Malignancy Consortium 061 protocol.","longName":"061_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Does the participant have the ability and willingness to give written informed consent","valueDescription":"Does the participant have the ability and willingness to give written informed consent","ValueMeaning":{"publicId":"2775209","version":"1","preferredName":"Does the participant have the ability and willingness to give written informed consent","longName":"2775209","preferredDefinition":"Does the participant have the ability and willingness to give written informed consent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E65CE3-2089-2D54-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-69FC-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","valueDescription":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","ValueMeaning":{"publicId":"2649473","version":"1","preferredName":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","longName":"2649473","preferredDefinition":"Is the participant, in the opinion of the Investigator, capable of complying with this protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651AA4-03DC-3BA1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6A06-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Date informed consent obtained","valueDescription":"Date informed consent obtained","ValueMeaning":{"publicId":"2580745","version":"1","preferredName":"Date informed consent obtained","longName":"2580745","preferredDefinition":"Date informed consent obtained","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6A10-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Participant's age (in years)","valueDescription":"Participant's age (in years)","ValueMeaning":{"publicId":"2649471","version":"1","preferredName":"Participant's age (in years)","longName":"2649471","preferredDefinition":"Participant's age (in years)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"326557B2-97F1-3BD4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6A1A-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Is the participant's life expectancy 3 months or more","valueDescription":"Is the participant's life expectancy 3 months or more","ValueMeaning":{"publicId":"2649470","version":"1","preferredName":"Is the participant's life expectancy 3 months or more","longName":"2649470","preferredDefinition":"Is the participant's life expectancy 3 months or more","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32651F9F-1D26-3BDA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6A24-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","valueDescription":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","ValueMeaning":{"publicId":"2775214","version":"1","preferredName":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","longName":"2775214","preferredDefinition":"Does the participant agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54E65CE3-2099-2D54-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6A97-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test within 72 hours before initiation of study drug dosing","valueDescription":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test within 72 hours before initiation of study drug dosing","ValueMeaning":{"publicId":"2936087","version":"1","preferredName":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test within 72 hours before initiation of study drug dosing","longName":"2936087","preferredDefinition":"If the participant is female, and of child-bearing potential, has she had a negative pregnancy test within 72 hours before initiation of study drug dosing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-6AA1-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6ABA-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Karnofsky Performance Status (must be > 60%)","valueDescription":"Karnofsky Performance Status (must be > 60%)","ValueMeaning":{"publicId":"2580739","version":"1","preferredName":"Karnofsky Performance Status (must be > 60%)","longName":"2580739","preferredDefinition":"Karnofsky Performance Status (must be > 60%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6AC4-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a CD4 count > 50 cells/uL","valueDescription":"Does the participant have a CD4 count > 50 cells/uL","ValueMeaning":{"publicId":"2936088","version":"1","preferredName":"Does the participant have a CD4 count > 50 cells/uL","longName":"2936088","preferredDefinition":"Does the participant have a CD4 count > 50 cells/uL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-6ACE-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6AE7-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Is the participant on stable anti-retroviral therapy for at least 4 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks after starting study drug","valueDescription":"Is the participant on stable anti-retroviral therapy for at least 4 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks after starting study drug","ValueMeaning":{"publicId":"2936090","version":"1","preferredName":"Is the participant on stable anti-retroviral therapy for at least 4 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks after starting study drug","longName":"2936090","preferredDefinition":"Is the participant on stable anti-retroviral therapy for at least 4 weeks with a PI-based or NNRTI-based regimen of at least three drugs, with no intention to change the regimen within 8 weeks after starting study drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-6B14-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6B2D-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test","valueDescription":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test","ValueMeaning":{"publicId":"2936091","version":"1","preferredName":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test","longName":"2936091","preferredDefinition":"Does the participant have serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-6B37-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6B50-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"If Yes, indicate cancer type (see protocol section 4.0 for specific eligibility criteria) NHL, KS, Renal Cell Cancer, Solid tumor, Hematologic malignancy","valueDescription":"If Yes, indicate cancer type (see protocol section 4.0 for specific eligibility criteria) NHL, KS, Renal Cell Cancer, Solid tumor, Hematologic malignancy","ValueMeaning":{"publicId":"2936092","version":"1","preferredName":"If Yes, indicate cancer type (see protocol section 4.0 for specific eligibility criteria) NHL, KS, Renal Cell Cancer, Solid tumor, Hematologic malignancy","longName":"2936092","preferredDefinition":"If Yes, indicate cancer type (see protocol section 4.0 for specific eligibility criteria) NHL, KS, Renal Cell Cancer, Solid tumor, Hematologic malignancy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-6B5A-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6B73-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Does the participant have a histologically or cytologically confirmed NHL, biopsy-proven KS or solid tumor or hematological malignancy","valueDescription":"Does the participant have a histologically or cytologically confirmed NHL, biopsy-proven KS or solid tumor or hematological malignancy","ValueMeaning":{"publicId":"2936093","version":"1","preferredName":"Does the participant have a histologically or cytologically confirmed NHL, biopsy-proven KS or solid tumor or hematological malignancy","longName":"2936093","preferredDefinition":"Does the participant have a histologically or cytologically confirmed NHL, biopsy-proven KS or solid tumor or hematological malignancy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-6B7D-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"720E24BA-6B96-DAC2-E040-BB89AD431225","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"ONEDATA","dateModified":"2009-08-26","deletedIndicator":"No"},{"value":"Creatinine within institutional normal limits or Glomerular filtration rate (GFR) > 60 mL/min/m^2 (calculated by the Cockcroft-Gault equation)","valueDescription":"Creatinine within institutional normal limits or Glomerular filtration rate (GFR) > 60 mL/min/m^2 (calculated by the Cockcroft-Gault equation)","ValueMeaning":{"publicId":"2961465","version":"1","preferredName":"Creatinine within institutional normal limits or Glomerular filtration rate (GFR) > 60 mL/min/m^2 (calculated by the Cockcroft-Gault equation)","longName":"2961465","preferredDefinition":"Creatinine within institutional normal limits or Glomerular filtration rate (GFR) > 60 mL/min/m^2 (calculated by the Cockcroft-Gault equation)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AC8450-5365-BCA8-E040-BB89AD4336B8","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78AC8450-537E-BCA8-E040-BB89AD4336B8","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"ONEDATA","dateModified":"2009-11-18","deletedIndicator":"No"},{"value":"Does the participant have the following laboratory parameters within 7 days prior to study entry Hemoglobin >= 8.0 gm/dL Absolute neutrophil count (ANC) >= 1500 cells/mm^3 Platelet count >= 100,000 /mm^3","valueDescription":"Does the participant have the following laboratory parameters within 7 days prior to study entry Hemoglobin >= 8.0 gm/dL Absolute neutrophil count (ANC) >= 1500 cells/mm^3 Platelet count >= 100,000 /mm^3","ValueMeaning":{"publicId":"2961466","version":"1","preferredName":"Does the participant have the following laboratory parameters within 7 days prior to study entry Hemoglobin >= 8.0 gm/dL Absolute neutrophil count (ANC) >= 1500 cells/mm^3 Platelet count >= 100,000 /mm^3","longName":"2961466","preferredDefinition":"Does the participant have the following laboratory parameters within 7 days prior to study entry Hemoglobin >= 8.0 gm/dL Absolute neutrophil count (ANC) >= 1500 cells/mm^3 Platelet count >= 100,000 /mm^3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AC8450-5388-BCA8-E040-BB89AD4336B8","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78AC8450-53A1-BCA8-E040-BB89AD4336B8","beginDate":"2009-11-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-11-18","modifiedBy":"ONEDATA","dateModified":"2009-11-18","deletedIndicator":"No"},{"value":"(If \"No) Is the elevated bilirubin felt to be secondary to Atazanavir therapy (If \"Yes\") Is direct bilirubin <= 1.5 times ULN AST (SGOT) and ALT (SGPT) <= 2.5 times the ULN","valueDescription":"(If \"No) Is the elevated bilirubin felt to be secondary to Atazanavir therapy (If \"Yes\") Is direct bilirubin <= 1.5 times ULN AST (SGOT) and ALT (SGPT) <= 2.5 times the ULN","ValueMeaning":{"publicId":"2982792","version":"1","preferredName":"(If \"No) Is the elevated bilirubin felt to be secondary to Atazanavir therapy (If \"Yes\") Is direct bilirubin <= 1.5 times ULN AST (SGOT) and ALT (SGPT) <= 2.5 times the ULN","longName":"2982792","preferredDefinition":"(If \"No) Is the elevated bilirubin felt to be secondary to Atazanavir therapy (If \"Yes\") Is direct bilirubin <= 1.5 times ULN AST (SGOT) and ALT (SGPT) <= 2.5 times the ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C96B8C2-F78B-24EC-E040-BB89AD435309","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C96B8C2-F7A4-24EC-E040-BB89AD435309","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"Total bilirubin <= 1.5 times ULN (upper limit of normal) (If \"No\") Is the elevated bilirubin felt to be secondary to Indinavir therapy (If \"Yes\") Is total bilirubin < 3.5 mg/dL and is direct bilirubin <= 1.5 times ULN","valueDescription":"Total bilirubin <= 1.5 times ULN (upper limit of normal) (If \"No\") Is the elevated bilirubin felt to be secondary to Indinavir therapy (If \"Yes\") Is total bilirubin < 3.5 mg/dL and is direct bilirubin <= 1.5 times ULN","ValueMeaning":{"publicId":"2982793","version":"1","preferredName":"Total bilirubin <= 1.5 times ULN (upper limit of normal) (If \"No\") Is the elevated bilirubin felt to be secondary to Indinavir therapy (If \"Yes\") Is total bilirubin < 3.5 mg/dL and is direct bilirubin <= 1.5 times ULN","longName":"2982793","preferredDefinition":"Total bilirubin <= 1.5 times ULN (upper limit of normal) (If \"No\") Is the elevated bilirubin felt to be secondary to Indinavir therapy (If \"Yes\") Is total bilirubin < 3.5 mg/dL and is direct bilirubin <= 1.5 times ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C96B8C2-F7AE-24EC-E040-BB89AD435309","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C96B8C2-F7C7-24EC-E040-BB89AD435309","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"},{"value":"If Yes, indicate HAART regimen type NNRTI-based only, Non ritonavir PI-based only, Ritonavir PI-based only, NNRTI- and non ritonavir PI-based, NNRTI- and ritonavir PI-based, Neither PI nor NNRTI based","valueDescription":"If Yes, indicate HAART regimen type NNRTI-based only, Non ritonavir PI-based only, Ritonavir PI-based only, NNRTI- and non ritonavir PI-based, NNRTI- and ritonavir PI-based, Neither PI nor NNRTI based","ValueMeaning":{"publicId":"2982794","version":"1","preferredName":"If Yes, indicate HAART regimen type NNRTI-based only, Non ritonavir PI-based only, Ritonavir PI-based only, NNRTI- and non ritonavir PI-based, NNRTI- and ritonavir PI-based, Neither PI nor NNRTI based","longName":"2982794","preferredDefinition":"If Yes, indicate HAART regimen type NNRTI-based only, Non ritonavir PI-based only, Ritonavir PI-based only, NNRTI- and non ritonavir PI-based, NNRTI- and ritonavir PI-based, Neither PI nor NNRTI based","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C96B8C2-F7D1-24EC-E040-BB89AD435309","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C96B8C2-F7EA-24EC-E040-BB89AD435309","beginDate":"2010-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"720E24BA-69E8-DAC2-E040-BB89AD431225","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"720D72EA-68EB-D075-E040-BB89AD433F48","latestVersionIndicator":"Yes","beginDate":"2009-08-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-26","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}